Corporate Vision February 2017

36 CORPORATE VISION / February 2017 , Zysis is a pharmaceutical development company looking to create a new treatment for psychotic, schizophrenic, bipolar and depressed patients. They are currently reaching out for partners to see their product all the way through to use in clinics and patient treatment. We contacted Vice President, Russ Pendleton, for more information. A Revolutionary Treatment of Psychotic Conditions Zysis is a privately-owned pharmaceutical company optimizing therapies for disorders of the Central Nervous System to improve sufferers’ lives. They are currently developing a new treatment in an area of unmet need; a once-weekly, oral tablet for the treatment of Psychotic conditions. The overall mission of Zysis is to create medicines that make it as easy as possible for patients to remember to take their medication. Any treatment that helps patients comply with therapy and therefore remain symptom-free is attractive to clinicians, carers and sufferers. The improvements their product makes in dosing convenience could make a very real difference to many patients’ lives. “Our inventiveness is unique”, Russ informed us. “We have created the first of a new type of treatment for these patients”. Those suffering with Schizophrenia, Schizoaffective Disorder and Bipolar Disorders. “It is patent protected.” The company itself is made up of its board members, who are all committed to the company through their investment in it. “We are all old, extremely experienced, and hope to be knowledgeable in the therapy area. Our culture is to use modern technology to communicate with each other whilst we are far apart. We do not have an office, just monthly meetings. “We work independently and at home as individuals. This allows us time to think instead of constantly feeling like you should be doing something in the office, we sit back, read scientific articles, stop, look at the sky, go for a walk…and think.” And this freedom to think has led to the production of a potentially revolutionary product. “There are other slow release products but these are injectable, ours is the only once weekly oral tablet.” “We have already sold the product to a partner for China, we would now like to find a partner for North and South America. The market is unlikely to support this product in Europe. We are in the controlled release section of the pharmaceutical market. “Our clients are our potential partners, to give them the best possible product, we work hard to ensure the best professional standards are achieved throughout the development and patent process.” The project itself will generate enough work for the company, and its partners, to last through to 2028. Russ signed off with a statement of confidence in his and his team’s product. “New products are constantly being launched in our field, however it is very unlikely that another oral once weekly therapy will be created as the properties of the active molecule are unique.” K Company: Zysis Name: Russ Pendleton Email: [email protected] Web Address: www.zysis.com Address: 58 Kingsway, London, SW14 7HW Telephone: 07878201416 1701CV26